Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43906591" target="_blank" >RIV/00216208:11120/12:43906591 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064211:_____/12:#0000213

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pubmed/23033284" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/23033284</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis

Popis výsledku v původním jazyce

Purpose: The objective of this study was to evaluate the feasibility, toxicity and efficacy of definitive radiochemotherapy with weekly cisplatin in head and neck cancer in a single institutional setting. Methods: Previously untreated patients with stageII-IV head and neck cancer were included. Radiotherapy consisted of 70 Gy/7 weeks/35 fractions. All patients received concurrent cisplatin 40 mg/m(2) weekly Results: Between 2/2002 and 8/2009, 148 consecutive patients (WHO <= 2, male to female ratio 6/1, median age 56 years) were treated. The mean follow-up was 40 months. Tumors of the oropharynx were the most frequent (46%) and stage IV predominated (80%). Eighty-nine percent of the patients had received the full radiation treatment as planned. Omission of weekly cisplatin occurred frequently, mainly because of hematological toxicity. Only 64% of the patients completed at least 5 cycles of chemotherapy. Grade 3/4 mucosal toxicity developed in 32% of the patients. The late toxicities w

Název v anglickém jazyce

Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis

Popis výsledku anglicky

Purpose: The objective of this study was to evaluate the feasibility, toxicity and efficacy of definitive radiochemotherapy with weekly cisplatin in head and neck cancer in a single institutional setting. Methods: Previously untreated patients with stageII-IV head and neck cancer were included. Radiotherapy consisted of 70 Gy/7 weeks/35 fractions. All patients received concurrent cisplatin 40 mg/m(2) weekly Results: Between 2/2002 and 8/2009, 148 consecutive patients (WHO <= 2, male to female ratio 6/1, median age 56 years) were treated. The mean follow-up was 40 months. Tumors of the oropharynx were the most frequent (46%) and stage IV predominated (80%). Eighty-nine percent of the patients had received the full radiation treatment as planned. Omission of weekly cisplatin occurred frequently, mainly because of hematological toxicity. Only 64% of the patients completed at least 5 cycles of chemotherapy. Grade 3/4 mucosal toxicity developed in 32% of the patients. The late toxicities w

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of BUON

ISSN

1107-0625

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

7

Strana od-do

471-477

Kód UT WoS článku

000309793000010

EID výsledku v databázi Scopus

—